RxDoctor Payments DataLook up a doctor →

Rebecca McCrery, MD

Urology · Omaha, NENPI 1316978695

Payments from drug & device makers

$624,491in general payments, 2019–2025

Across 504 payments — averaging $1239.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bluewind Medical$293K
  • Axonics, Inc.$196K
  • Provepharm Inc.$54K
  • Medtronic$35K
  • Boston Scientific$23K
  • Astellas Pharma US Inc$9K
  • plus $15K from 32 others
$63,459in research payments, 2019–2025

Across 27 payments — averaging $2350.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Coloplast$63K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$624,491 in reported general payments places this provider in the 95th percentile of 79 urology providers in Nebraska.

See all urology providers in Nebraska

Medicare billing

Part B allowed, 2024
$564,980
Medicare patients
731
Services billed
10,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other urology in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →